Myovant Sciences Ltd. (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Acquires 37,913 Shares of Stock

Myovant Sciences Ltd. (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo acquired 37,913 shares of Myovant Sciences stock in a transaction that occurred on Friday, September 17th. The shares were bought at an average price of $22.79 per share, with a total value of $864,037.27. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chemical Co. Ltd. Sumitomo also recently made the following trade(s):

  • On Wednesday, September 15th, Chemical Co. Ltd. Sumitomo bought 89,864 shares of Myovant Sciences stock. The shares were acquired at an average cost of $21.98 per share, for a total transaction of $1,975,210.72.
  • On Monday, September 13th, Chemical Co. Ltd. Sumitomo bought 83,178 shares of Myovant Sciences stock. The shares were acquired at an average cost of $23.38 per share, for a total transaction of $1,944,701.64.
  • On Friday, September 10th, Chemical Co. Ltd. Sumitomo acquired 30,000 shares of Myovant Sciences stock. The stock was purchased at an average cost of $25.11 per share, for a total transaction of $753,300.00.
  • On Tuesday, September 7th, Chemical Co. Ltd. Sumitomo bought 33,200 shares of Myovant Sciences stock. The stock was bought at an average price of $26.23 per share, for a total transaction of $870,836.00.
  • On Friday, September 3rd, Chemical Co. Ltd. Sumitomo bought 31,200 shares of Myovant Sciences stock. The stock was bought at an average price of $26.76 per share, for a total transaction of $834,912.00.
  • On Monday, August 30th, Chemical Co. Ltd. Sumitomo purchased 70,000 shares of Myovant Sciences stock. The shares were acquired at an average price of $23.92 per share, for a total transaction of $1,674,400.00.
  • On Friday, August 27th, Chemical Co. Ltd. Sumitomo purchased 37,038 shares of Myovant Sciences stock. The shares were acquired at an average price of $23.17 per share, for a total transaction of $858,170.46.
  • On Wednesday, August 25th, Chemical Co. Ltd. Sumitomo bought 28,709 shares of Myovant Sciences stock. The stock was purchased at an average price of $22.44 per share, for a total transaction of $644,229.96.
  • On Monday, August 23rd, Chemical Co. Ltd. Sumitomo purchased 55,447 shares of Myovant Sciences stock. The stock was bought at an average cost of $22.30 per share, with a total value of $1,236,468.10.
  • On Friday, August 20th, Chemical Co. Ltd. Sumitomo purchased 46,478 shares of Myovant Sciences stock. The stock was bought at an average cost of $20.86 per share, with a total value of $969,531.08.

MYOV stock opened at $22.11 on Tuesday. The company has a market cap of $2.04 billion, a P/E ratio of -7.06 and a beta of 2.87. Myovant Sciences Ltd. has a twelve month low of $13.42 and a twelve month high of $30.90. The business’s fifty day moving average is $21.94 and its 200-day moving average is $21.66.

Myovant Sciences (NYSE:MYOV) last issued its quarterly earnings data on Wednesday, July 28th. The company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.46). The company had revenue of $41.06 million during the quarter, compared to analyst estimates of $61.19 million. Analysts predict that Myovant Sciences Ltd. will post -2.24 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in MYOV. Commonwealth Equity Services LLC grew its holdings in shares of Myovant Sciences by 4.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 12,078 shares of the company’s stock valued at $275,000 after acquiring an additional 500 shares in the last quarter. Citigroup Inc. grew its holdings in shares of Myovant Sciences by 56.8% in the 1st quarter. Citigroup Inc. now owns 1,620 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Myovant Sciences by 7.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 13,156 shares of the company’s stock valued at $299,000 after acquiring an additional 860 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Myovant Sciences by 1.0% in the 2nd quarter. Northern Trust Corp now owns 90,526 shares of the company’s stock valued at $2,061,000 after acquiring an additional 892 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Myovant Sciences by 211.6% in the 1st quarter. Royal Bank of Canada now owns 1,480 shares of the company’s stock valued at $31,000 after acquiring an additional 1,005 shares in the last quarter. Hedge funds and other institutional investors own 33.78% of the company’s stock.

Several equities analysts recently weighed in on the company. Zacks Investment Research cut Myovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, August 10th. SVB Leerink assumed coverage on Myovant Sciences in a research note on Thursday, September 9th. They set a “market perform” rating and a $24.00 price target on the stock. The Goldman Sachs Group assumed coverage on Myovant Sciences in a research note on Friday, August 20th. They set a “neutral” rating and a $18.00 price target on the stock. Finally, JMP Securities reiterated a “buy” rating on shares of Myovant Sciences in a research note on Wednesday, August 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Myovant Sciences has a consensus rating of “Hold” and an average price target of $25.57.

Myovant Sciences Company Profile

Myovant Sciences, Inc is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women’s health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer.

Read More: Dual Listing What You Need to Know

Insider Buying and Selling by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.